Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
MTMolecular Templates, Inc. logo

Molecular Templates, Inc. (MTEM)

Other OTC · Currency in USD
$0.00 ▼ 0.00 (0.00%)
At close: Aug 13, 9:30 AM ET. Market closed.
$0.11 ▲ +0.11 (+107,100.00%)
After hours: Feb 10, 4:00 PM ET

Summary

Previous Close
$0.00
Open
$0.00
Day's Range
$0.00 – $0.00
52 Week Range
$0.00 – $1.59
Volume
5
Avg. Volume
2,380
Market Cap
$658
Beta (5Y Monthly)
1.53
PE Ratio (TTM)
--
EPS (TTM)
-$1.80
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Molecular Templates, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
62
CEO
Eric E. Poma
Website
mtem.com

Molecular Templates, Inc. (MTEM) is a clinical-stage biopharmaceutical firm dedicated to the identification and progression of biological therapies for oncology and other significant health conditions. The company's core development strategy relies on its unique engineered toxin body (ETB) drug platform to construct a robust pipeline of treatments. Currently, several of its ETB candidates are undergoing Phase I clinical evaluation: MT-5111 is being assessed for HER2-positive cancers; MT-0169 is in trials for individuals with relapsed or refractory myeloma; and MT-6402 targets patients who have not responded to prior PD-1/PD-L1 antibody treatments.

Earnings

DateEst.Actual
Aug 14, 2024-$1.44-$1.23Beat
May 15, 2024-$0.78$0.08Beat
Mar 29, 2024-$0.97-$0.73Beat
Nov 13, 2023-$2.70-$0.82Beat
Aug 10, 2023-$5.17-$2.85Beat
May 15, 2023-$0.31$2.85Beat

Analyst view

Rating: Buy
Buy 75% · Hold 13% · Sell 13%

Get free alerts on MTEM and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.